2023 World Conference on Lung Cancer (Posters)-P1.22. A Phase 3 Multicenter Study to Evaluate the Feasibility of a New NGS Panel Using Cytological Specimens for NSCLC

P1.22. A Phase 3 Multicenter Study to Evaluate the Feasibility of a New NGS Panel Using Cytological Specimens for NSCLC - PDF(Abstract)

Back to course

Pdf Summary

In this study, researchers aimed to evaluate the feasibility of a new next-generation sequencing (NGS) panel test called the lung cancer compact panel (LCCP) using cytological specimens for non-small cell lung cancer (NSCLC). The LCCP is an amplicon-based high sensitivity panel capable of measuring eight druggable genes. The study enrolled consecutive patients who underwent diagnostic procedures for lung cancer from March 2022 to March 2023. Cytology samples were collected using various methods and stored in tubes containing nucleic acid protection agents. The primary endpoint of the study was the analysis success rate, defined as a nucleic acid yield of 10 ng or more for DNA/RNA and successful analysis of all 8 genes. The secondary endpoint was the gene mutation detection rate by LCCP. <br /><br />The study included 248 cases, with an average age of 70.3 years and a majority of male patients. The clinical stages of the patients were 1/2/3/4: 13.3/10.1/23.0/53.2%, and the pathological types were Ad./Sq./Sm./NOS: 61.7/16.9/11.3/7.7%, respectively. The cytological samples were collected through bronchoscopy, percutaneous needle puncture, or effusion. The analysis success rate using LCCP for cytology samples was 98.4%. Among the cases of lung adenocarcinoma, 62% showed genetic mutations detected by LCCP, including mutations in genes such as EGFR, KRAS, ALK, BRAF, RET, MET, HER2, and ROS1.<br /><br />The researchers concluded that the success rate for genetic mutation analysis of cytology samples using LCCP was high and superior to conventional panel testing. The gene mutation detection rate was also high. They suggest that as lung cancer gene panels become simpler to use and less invasive, they may become more popular in clinical practice. This study provides evidence for the feasibility and effectiveness of using the LCCP NGS panel with cytological specimens in the diagnosis and genetic analysis of NSCLC.

Asset Subtitle

Kei Morikawa

Meta Tag

Speaker Kei Morikawa

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

next-generation sequencing

lung cancer compact panel

cytological specimens

non-small cell lung cancer

druggable genes

gene mutation detection

lung adenocarcinoma

EGFR

KRAS

ALK